Vertex kidney disease pipeline: Full Pove data support approval; commercialization hinges on payer coverage and new patients

What new conclusions do the full Pove data support?

The full phase three results for Pove in IgA nephropathy are consistent with the previously disclosed topline data, with no new safety signals. Morgan Stanley therefore maintained its Overweight rating; the update reinforced its existing view without an upward revision to the efficacy figures.
At week 36, Pove produced a placebo-adjusted reduction in the urine protein-to-creatinine ratio (UPCR) of 49.8%; Voyxact and Trutakna recorded 51.2% and 42%, respectively, at the same point in their own trials. These are cross-trial comparisons; Morgan Stanley sees competitive strength in the combination of efficacy, safety, dosing every four weeks and a low-volume autoinjector.
Pove’s UPCR benefit extended across all prespecified subgroups, including patients in and outside North America, supporting the consistency of its efficacy across different study populations.

In cross-trial observations, Pove produced a slightly greater reduction in immunoglobulin IgG than Voyxact, but there was no imbalance in infection risk between groups. No trial participant stopped treatment because IgG fell below the protocol-specified threshold of 150 mg/dL, and none received immunoglobulin infusions.
Anti-drug antibodies were observed in the trial; the company said they did not affect efficacy or the risk profile. Vertex is confident in the prospects for approval before the 30 November regulatory decision date and expects the monitoring requirements on the drug label to match those of approved competitors; this is a key expectation for convenience of use after launch.

Vertex expects Pove’s main source of patients to be people who have not previously received relevant treatment, rather than patients switching from Voyxact or Trutakna. Its commercialization plan therefore depends more on expanding the patient base than on competing for existing users of rival products.
The company previously said it would deploy a kidney disease sales team larger than those of competitors and began engaging with payers in July 2025. It expects to announce specific coverage progress in the first half of 2027. While payer coverage has yet to be secured, the company is preparing a bridge treatment support program and expects payers not to require patients to try other drugs first.
Morgan Stanley estimates Pove’s risk-adjusted global sales in 2035 at 8.8 billion dollars, including 6.5 billion dollars from IgA nephropathy; its model assigns probabilities of success of 90% and 70% to IgA nephropathy and primary membranous nephropathy, respectively. Gaining meaningful market share is an important condition for realizing this sales potential.

The phase two AMPLIFIED study of inaxaplin includes patients with moderate proteinuria and AMKD patients with type 2 diabetes, with no overlap with the phase three AMPLITUDE population. The reduction in proteinuria observed so far in the diabetes cohort has been relatively modest; clinical experts invited by the company believe that a sustained reduction of 20% or 25% could improve the glomerular filtration rate.
Phase three AMPLITUDE is scheduled to report interim data in early 2027. Vertex reiterated that the basis for accelerated approval agreed with the FDA is the one-year estimated glomerular filtration rate (eGFR), making kidney function benefit the key threshold. The interim analysis covers several hundred patients, and the final analysis will include more than 500 patients.
Morgan Stanley assigns inaxaplin a 50% probability of success and estimates risk-adjusted global sales of 2.3 billion dollars in 2035, with less certainty in the model than for Pove.